Molecular structures provide roadmap for targeted Parkinson's disease therapeutics
Researchers at Weill Cornell Medicine have uncovered how a key Parkinson's protein called LRRK2 shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state. Mutations that cause LRRK2 to become abnormally active are among the most common genetic causes of Parkinson's disease. Even without these mutations,…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
